2-TUR QANDLI DIABET BILAN KASALLANGAN BEMORLARDA SGLT2 INGIBITORLARI VA METFORMIN KOMBINATSIYASI BILAN DAVOLASHNING SAMARADORLIGI
Keywords:
2-tur qandli diabet, SGLT2 ingibitorlari, metformin, HbA1c, glikemik nazorat, yurak-qon tomir kasalliklari, buyrak yetishmovchiligi, dapagliflozin, empagliflozin, kanagliflozin.Abstract
Mazkur maqolada 2-tur qandli diabet bilan kasallangan bemorlarda natriy-glyukoza kotransportyor-2 (SGLT2) ingibitorlari hamda metformin kombinatsiyasining klinik samaradorligi tahlil qilinadi. Tadqiqot davomida ushbu kombinatsiyaning glikemik nazoratga, glikirlangan gemoglobin (HbA1c) darajasiga, tana vazniga, arterial qon bosimiga, yurak-qon tomir xavfiga hamda buyrak faoliyatiga ta’siri ilmiy manbalar asosida o‘rganildi. SGLT2 ingibitorlari va metformin kombinatsiyasi insulin rezistentligini kamaytirishi, glyukozaning siydik orqali chiqarilishini kuchaytirishi hamda gipoglikemiya xavfini minimal darajada ushlab turishi aniqlangan. Tadqiqot natijalari ushbu kombinatsiyaning yurak-qon tomir asoratlari va surunkali buyrak kasalligi xavfini kamaytirishda samarali ekanligini ko‘rsatadi. Zamonaviy xalqaro tavsiyalar ushbu kombinatsiyani 2-tur diabetni davolashning asosiy yo‘nalishlaridan biri sifatida tavsiya etmoqda.
References
International Diabetes Federation. IDF Diabetes Atlas. 10-nashr. Brussels, 2021. 34–56-betlar.
Rena G., Hardie D.G., Pearson E.R. The mechanisms of action of metformin. Diabetologia. 2017. Vol. 60(9). 1577–1585-betlar.
Abdul-Ghani M.A., Norton L., DeFronzo R.A. Role of sodium-glucose cotransporter 2 inhibitors in the treatment of type 2 diabetes. Endocrine Reviews. 2015. Vol. 36(5). 515–531-betlar.
Zinman B., Wanner C. et al. Empagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine. 2015. Vol. 373. 2117–2128-betlar.
Zinman B., Inzucchi S.E. Cardiovascular benefits of SGLT2 inhibitors. Circulation. 2016. Vol. 134(10). 752–772-betlar.
Wiviott S.D., Raz I. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine. 2019. Vol. 380. 347–357-betlar.
Neal B., Perkovic V. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine. 2017. Vol. 377. 644–657-betlar.
Ferrannini E., Solini A. SGLT2 inhibition in diabetes mellitus. Nature Reviews Endocrinology. 2018. Vol. 14. 495–508-betlar.
Heerspink H.J.L., Stefansson B.V. et al. Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine. 2020. Vol. 383. 1436–1446-betlar.
Perkovic V., Jardine M.J. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine. 2019. Vol. 380. 2295–2306-betlar.
American Diabetes Association. Standards of Medical Care in Diabetes—2025. Diabetes Care. 2025. Vol. 48(Suppl.1). S1–S350-betlar.
Davies M.J., Aroda V.R. et al. Management of hyperglycemia in type 2 diabetes, 2022 consensus report by the ADA and EASD. Diabetes Care. 2022. Vol. 45(11). 2753–2786-betlar.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles published in IQRO — Scientific Methodological Journal are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Authors retain copyright and grant the journal the right of first publication.
Users may read, download, copy, distribute, print, search, or link to the full texts of articles, provided that the original authors and the journal are properly cited.
Published materials may be used, distributed, and reproduced in any medium, provided that the original work is properly cited.



Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo